Allergan 8-K Allergan Reports Third Quarter Operating Results

Exhibit 99.1

ALLERGAN REPORTS THIRD QUARTER OPERATING RESULTS

§      Total Product Net Sales Increased 24 Percent for the Third Quarter

§      Board of Directors Declares Third Quarter Dividend

(IRVINE, Calif., November 6, 2007) — Allergan, Inc. (NYSE: AGN) today announced operating results for the quarter ended September 28, 2007. Allergan also announced that its Board of Directors has declared a third quarter dividend of $0.05 per share, payable on November 30, 2007 to stockholders of record on November 9, 2007.

Operating Results
For the quarter ended September 28, 2007:

• Allergan reported $0.50 diluted earnings per share from continuing operations compared to $0.35 diluted earnings per share reported for the third quarter of 2006.

• Allergan’s adjusted diluted earnings per share from continuing operations were $0.58 in the third quarter of 2007, compared to adjusted diluted earnings per share of $0.47 in the third quarter of 2006, a 23.4% year- over-year increase. Adjusted diluted earnings per share for the third quarters of 2007 and 2006 exclude the non-GAAP adjustments to diluted earnings per share that are contained in the financial tables of this press release.

Product Sales
For the quarter ended September 28, 2007:

• Allergan’s total product net sales were $978.7 million. Total product net sales increased 23.6 percent, or 20.9 percent at constant currency, compared to total product net sales in the third quarter of 2006.

° Total specialty pharmaceuticals net sales increased 16.1 percent, or 13.4 percent at constant currency, compared to total specialty pharmaceuticals net sales in the third quarter of 2006.

° Total core medical devices net sales increased 66.0 percent, or 62.7 percent at constant currency, compared to total core medical devices net sales in the third quarter of 2006.

“Allergan operates in a wide range of exceptionally high growth global medical device and specialist biopharmaceutical markets where we play a market leadership role with many innovative products. These dynamics have led to another quarter of superb sales and earnings growth,” said David E.I. Pyott, Allergan’s Chairman of the Board and Chief Executive Officer. “Furthermore, beyond these current opportunities, recently supplemented by the FDA approval of COMBIGAN™, our vigorous investment into R&D as well as our entry into urologics should fuel additional growth over the long-term.”

-more-

2-2-2 

Product and Pipeline Update
During the third quarter of 2007:

• In July 2007, Apotex filed a Petition for Writ of Certiorari in the United States Supreme Court regarding the affirmation by the United States Court of Appeals for the Federal Circuit of the district court’s ruling in favor of Allergan and Roche Palo Alto, LLC, formerly known as Syntex (U.S.A.) LLC, in a patent infringement lawsuit against Apotex, Inc., Apotex Corp., and Novex Pharma (the “Defendants”). The district court’s ruling prevents the Defendants, together with all persons and entities acting in concert with the Defendants, from obtaining U.S. Food and Drug Administration (FDA) approval to market a generic version of Allergan’s product ACULAR^® (ketorolac tromethamine ophthalmic solution) 0.5% and enjoins the Defendants from manufacturing or selling their product before U.S. Patent No. 5,110,493 expires in 2009. On October 1, 2007, the Supreme Court of the United States denied Apotex’s Petition for Writ of Certiorari.

• In August 2007, in connection with our settlement of certain European litigation with Merz, we granted Merz a global, royalty-bearing license for patents and patent applications relating to a neurotoxic component of botulinum toxin of any serotype for all therapeutic and aesthetic uses, except for any genitourinary, gastrointestinal and prostate diseases, hyperhidrosis and headache. We believe the value of our botulinum toxin patent estate is demonstrated by the Merz license, as well as the license previously granted to Elan Corporation, which was subsequently sold by Elan to Solstice Neurosciences.

• On September 19, 2007, Allergan announced that Allergan and Esprit Pharma Holding Company, Inc. entered into an agreement pursuant to which Allergan would acquire privately held Esprit Pharma, Inc. (Esprit) for approximately $370 million in an all-cash transaction. On October 17, 2007, Allergan announced that it completed the Esprit acquisition and will commence the integration of Esprit into Allergan. The Esprit acquisition supports Allergan’s U.S. growth strategy and demonstrates Allergan’s focus on strengthening its core pharmaceutical businesses by creating a dedicated urologics division to serve urologists and their patients.

• Allergan and Stiefel Laboratories, Inc. entered into a strategic collaboration to develop and market new products involving Tazarotene for dermatological use worldwide, and to co-promote TAZORAC® in the United States, further strengthening and expanding Allergan’s reach into the dermatology market.

Following the end of the third quarter of 2007:

• On October 31, 2007, Allergan announced that the U.S. Food and Drug Administration approved COMBIGAN™ (brimonidine tartrate/timolol maleate ophthalmic solution) 0.2%/0.5%, an alpha adrenergic receptor agonist with a beta adrenergic receptor inhibitor, for the reduction of elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension who require adjunctive or replacement therapy due to inadequately controlled IOP.

-more-

3-3-3 

Discontinued Operations
On July 2, 2007, Allergan and Croma-Pharma completed the sale of the ophthalmic surgical business that Allergan obtained in connection with its January 2007 acquisition of Groupe Corneal Laboratoires. The first and second quarters of 2007 have been retrospectively revised for the discontinued operations associated with this sale and are contained in the financial tables of this press release.

Outlook
For the full year of 2007:

• Allergan is increasing guidance as follows:

°	Total product net sales to between $3,775 million and $3,820 million.
°	Total specialty pharmaceuticals net sales to between $3,045 million and $3,055 million. Total specialty pharmaceuticals net sales exclude sales of products acquired in connection with the Inamed, Corneal and EndoArt acquisitions.
°	ALPHAGAN® Franchise product net sales to between $320 million and $330 million.
°	BOTOX® product net sales to between $1,185 million and $1,195 million.
°	Obesity intervention product net sales to between $260 million and $275 million.
°	Facial aesthetics product net sales to between $185 million and $195 million.
°	Selling, General and Administrative ratio to product net sales guidance to between 41% and 42%.

• Allergan is tightening the expected guidance range as follows:

°	LUMIGAN® Franchise product net sales to between $380 million and $390 million.
°	RESTASIS® product net sales to between $330 million and $340 million.
°	Breast aesthetics product net sales to between $285 million and $295 million.

• Allergan estimates full year adjusted diluted earnings per share from continuing operations of between $2.14 and $2.15, which assumes approximately $0.04 of dilution per share resulting from the Esprit acquisition. Adjusted diluted earnings per share guidance excludes the non-GAAP adjustments to diluted earnings per share guidance that are contained in the financial tables of this press release.

• All other guidance provided on August 1, 2007 remains unchanged.

For the fourth quarter of 2007, Allergan estimates:

• Total product net sales between $975 million and $1,020 million.

• Adjusted diluted earnings per share from continuing operations guidance of between $0.56 and $0.57, which assumes approximately $0.04 of dilution per share resulting from the Esprit acquisition. Adjusted diluted earnings per share guidance excludes the non-GAAP adjustments to diluted earnings per share guidance that are contained in the financial tables of this press release.

All references in this press release to average number of shares outstanding and per share amounts have been retrospectively revised to reflect the two-for-one stock split effected in the form of a stock dividend payable on June 22, 2007 to stockholders of record on June 11, 2007.

-more-

4-4-4

Forward-Looking Statements
In this press release, the statements regarding product development, market potential, expected growth, the statements by Mr. Pyott as well as the outlook for Allergan’s earnings per share and revenue forecasts, among other statements above, are forward-looking statements. Because forecasts are inherently estimates that cannot be made with precision, Allergan’s performance at times differs materially from its estimates and targets, and Allergan often does not know what the actual results will be until after a quarter’s end and year’s end. Therefore, Allergan will not report or comment on its progress during a current quarter except through public announcement. Any statement made by others with respect to progress during a current quarter cannot be attributed to Allergan.

Any other statements in this press release that refer to Allergan’s expected, estimated or anticipated future results are forward-looking statements. All forward-looking statements in this press release reflect Allergan’s current analysis of existing trends and information and represent Allergan’s judgment only as of the date of this press release. Actual results may differ materially from current expectations based on a number of factors affecting Allergan’s businesses, including, among other things, changing competitive, market and regulatory conditions; the timing and uncertainty of the results of both the research and development and regulatory processes; domestic and foreign health care and cost containment reforms, including government pricing and reimbursement policies; technological advances and patents obtained by competitors; the performance, including the approval, introduction, and consumer and physician acceptance of new products and the continuing acceptance of currently marketed products; the effectiveness of advertising and other promotional campaigns; the timely and successful implementation of strategic initiatives; the results of any pending or future litigations, investigations or claims; the uncertainty associated with the identification of and successful consummation and execution of external corporate development initiatives and strategic partnering transactions; and Allergan’s ability to obtain and successfully maintain a sufficient supply of products to meet market demand in a timely manner. In addition, matters generally affecting the economy, such as changes in interest and currency exchange rates; international relations; and the state of the economy worldwide can materially affect Allergan’s results. Therefore, the reader is cautioned not to rely on these forward-looking statements. Allergan expressly disclaims any intent or obligation to update these forward-looking statements except as required to do so by law.

Additional information concerning the above-referenced risk factors and other risk factors can be found in press releases issued by Allergan, as well as Allergan’s public periodic filings with the Securities and Exchange Commission, including the discussion under the heading “Risk Factors” in Allergan’s 2006 Form 10-K and Allergan’s Form 10-Q for the period ended June 29, 2007. Copies of Allergan’s press releases and additional information about Allergan is available at www.allergan.com or you can contact the Allergan Investor Relations Department by calling 714-246-4636.

-more-

5-5-5

About Allergan, Inc.
With more than 55 years of experience providing high-quality, science-based products, Allergan, Inc., with headquarters in Irvine, California, discovers, develops and commercializes products in the ophthalmology, neurosciences, medical dermatology, medical aesthetics, obesity intervention, urologics and other specialty markets that deliver value to its customers, satisfy unmet medical needs, and improve patients’ lives.

Allergan Contacts
Jim Hindman (714) 246-4636 (investors)
Joann Bradley (714) 246-4766 (investors)
Emil Schultz (714) 246-4474 (investors)
Caroline Van Hove (714) 246-5134 (media)

® and TM Marks owned by Allergan, Inc.
ACULAR® is a registered trademark of Roche Palo Alto, LLC

-more-

6-6-6

ALLERGAN, INC.
Condensed Consolidated Statements of Operations and
Reconciliation of Non-GAAP Adjustments
(Unaudited)

	Three months ended
In millions, except per share amounts	September 28, 2007									September 29, 2006
				Non-GAAP									Non-GAAP
	GAAP			Adjustments			Adjusted			GAAP			Adjustments			Adjusted
Revenues
Product net sales	$	978.7		$	—		$	978.7		$	791.7		$	—		$	791.7
Other revenues		15.0			—			15.0			15.1			—			15.1
		993.7			—			993.7			806.8			—			806.8
Operating costs and expenses
Cost of sales (excludes amortization of acquired intangible assets)		173.5			(0.7	)(a)		172.8			167.7			(24.1	)(h)(i)		143.6
Selling, general and administrative		395.6			(1.9	)(b)		393.7			364.0			(33.6	)(h)(j)(k)		330.4
Research and development		164.4			—			164.4			120.4			(0.1	)(j)		120.3
Amortization of acquired intangible assets		28.7			(23.5	)(c)		5.2			24.9			(19.6	)(c)		5.3
Restructuring charges		11.0			(11.0	)(d)		—			8.6			(8.6	)(d)		—
Operating income		220.5			37.1			257.6			121.2			86.0			207.2
Non-operating income (expense)
Interest income		18.4			—			18.4			12.8			—			12.8
Interest expense		(17.5	)		—			(17.5	)		(11.9	)		(4.3	)(l)		(16.2	)
Unrealized gain (loss) on derivative instruments, net		0.4			(0.4	)(e)		—			0.2			(0.2	)(e)		—
Gain on investments		—			—			—			0.1			—			0.1
Other, net		(10.5	)		—			(10.5	)		(1.7	)		—			(1.7	)
		(9.2	)		(0.4	)		(9.6	)		(0.5	)		(4.5	)		(5.0	)
Earnings from continuing operations before income taxes and minority interest		211.3			36.7			248.0			120.7			81.5			202.2
Provision for income taxes		55.3			12.8	(f)		68.1			14.3			43.1	(m)		57.4
Earnings from continuing operations		156.0			23.9			179.9			106.4			38.4			144.8
Discontinued operations:
Earnings from discontinued operations, net of applicable income tax of $0.8 million		1.4			(1.4	)(g)		—			—			—			—
Gain on sale of discontinued operations, net of tax of $0.9 million		—			—			—			—			—			—
Discontinued operations		1.4			(1.4	)		—			—			—			—
Net earnings	$	157.4		$	22.5		$	179.9		$	106.4		$	38.4		$	144.8
Basic earnings per share:
Continuing operations	$	0.51					$	0.59		$	0.35					$	0.48
Discontinued operations		—						—			—						—
Net basic earnings per share	$	0.51					$	0.59		$	0.35					$	0.48
Diluted earnings per share:
Continuing operations	$	0.50					$	0.58		$	0.35					$	0.47
Discontinued operations		0.01						—			—						—
Net diluted earnings per share	$	0.51					$	0.58		$	0.35					$	0.47
Weighted average number of common shares outstanding:
Basic		305.9						305.9			301.8						301.8
Diluted		309.3						309.3			305.1						305.1
Selected ratios as a percentage of product net sales
Selling, general and administrative		40.4	%					40.2	%		46.0	%					41.7	%
Research and development		16.8	%					16.8	%		15.2	%					15.2	%

(a) Corneal fair market value inventory roll-out adjustment of $0.5 million and integration and transition costs related to the acquisition of Corneal and Inamed of $0.2 million

-more-

7-7-7

(b)	Integration and transition costs related to the acquisitions of Corneal and Inamed of $1.2 million and $0.7 million, respectively
(c)	Amortization of acquired intangible assets
(d)	Net restructuring charges
(e)	Unrealized gain (loss) on the mark-to-market adjustment to derivative instruments
(f)	Total tax effect for non-GAAP pre-tax adjustments
(g)	Discontinued operations
(h)	Integration and transition costs related to the acquisition of Inamed, consisting of Cost of sales of $0.2 million and Selling, general and administrative expense of $4.9 million
(i)	Inamed fair-market value inventory adjustment roll-out of $23.9 million
(j)	Transition/duplicate operating expenses, consisting of Selling, general and administrative expense of $0.2 million and Research and development expense of $0.1 million
(k)	Contribution to Allergan Foundation of $28.5 million
(l)	Reversal of interest expense related to resolution of uncertain tax positions
(m)	Total tax effect for non-GAAP pre-tax adjustments and other income tax adjustments, consisting of the following amounts (in millions):

	Tax effect
Non-GAAP pre-tax adjustments of $81.5 million	$	(27.8	)
Resolution of uncertain tax positions		3.9
Change in valuation allowance		(17.2	)
Taxes related to intercompany transfers of trade businesses and net assets		0.8
Change in estimated income taxes on 2005 dividend repatriation		(2.8	)
	$	(43.1	)

“GAAP” refers to financial information presented in accordance with generally accepted accounting principles in the United States.

This press release includes non-GAAP financial measures, as defined in Regulation G promulgated by the Securities and Exchange Commission, with respect to the three and nine months ended September 28, 2007 and September 29, 2006 and with respect to anticipated results for the fourth quarter and full year of 2007. Allergan believes that its presentation of non-GAAP financial measures provides useful supplementary information to investors regarding its operational performance because it enhances an investor’s overall understanding of the financial performance and prospects for the future of Allergan’s core business activities by providing a basis for the comparison of results of core business operations between current, past and future periods. The presentation of historical non-GAAP financial measures is not meant to be considered in isolation from or as a substitute for results prepared in accordance with accounting principles generally accepted in the United States.

In this press release, Allergan reported the non-GAAP financial measure “adjusted earnings” and related “adjusted diluted earnings per share.” Allergan uses adjusted earnings to enhance the investor’s overall understanding of the financial performance and prospects for the future of Allergan’s core business activities. Adjusted earnings is one of the primary indicators management uses for planning and forecasting in future periods, including trending and analyzing the core operating performance of Allergan’s business from period to period without the effect of the non-core business items indicated. Management uses adjusted earnings to prepare operating budgets and forecasts and to measure Allergan’s performance against those budgets and forecasts on a corporate and segment level. Allergan also uses adjusted earnings for evaluating management performance for compensation purposes.

Despite the importance of adjusted earnings in analyzing Allergan’s underlying business, the budgeting and forecasting process and designing incentive compensation, adjusted earnings has no standardized meaning defined by GAAP. Therefore, adjusted earnings has limitations as an analytical tool, and should not be considered in isolation, or as a substitute for analysis of Allergan’s results as reported under GAAP. Some of these limitations are:

• it does not reflect cash expenditures, or future requirements, for expenditures relating to restructurings, and certain acquisitions, including severance and facility transition costs associated with acquisitions;

• it does not reflect gains or losses on the disposition of assets associated with restructuring and business exit activities;

• it does not reflect the tax benefit or tax expense associated with the items indicated;

• it does not reflect the impact on earnings of charges resulting from certain matters Allergan considers not to be indicative of its on-going operations; and

• other companies in Allergan’s industry may calculate adjusted earnings differently than it does, which may limit its usefulness as a comparative measure.

Allergan compensates for these limitations by using adjusted earnings only to supplement net income (loss) on a basis prepared in conformance with GAAP in order to provide a more complete understanding of the factors and trends affecting its business. Allergan strongly encourages investors to consider both net earnings (loss) and cash flows determined under GAAP as compared to adjusted earnings, and to perform their own analysis, as appropriate.

-more-

8-8-8

ALLERGAN, INC.
Condensed Consolidated Statements of Operations and
Reconciliation of Non-GAAP Adjustments
(Unaudited)

	Nine months ended
In millions, except per share amounts	September 28, 2007										September 29, 2006
				Non-GAAP											Non-GAAP
	GAAP			Adjustments			Adjusted							GAAP		Adjustments		Adjusted
Revenues
Product net sales	$	2,803.9		$	—			$	2,803.9			$	2,193.9		$	—		$	2,193.9
Other revenues		44.4			—				44.4				40.3			—			40.3
		2,848.3			—				2,848.3				2,234.2			—			2,234.2
Operating costs and expenses
Cost of sales (excludes amortization of acquired intangible assets)		493.4			(0.7	)(a)			492.7				433.2			(48.6	)(j)(k)		384.6
Selling, general and administrative		1,215.1			(19.8	)(b)			1,195.3				975.4			(48.8	)(j)(l)(m)		926.6
Research and development		528.4			(72.0	)(c)			456.4				930.1			(580.0	)(j)(l)(n)		350.1
Amortization of acquired intangible assets		86.1			(70.0	)(d)			16.1				54.8			(39.1	)(d)		15.7
Restructuring charges		24.3			(24.3	)(e)			—				17.1			(17.1	)(e)		—
Operating income		501.0			186.8				687.8				(176.4	)		733.6			557.2
Non-operating income (expense)
Interest income		48.6			(0.4	)(f)			48.2				34.3			4.9	(o)		39.2
Interest expense		(53.5	)		—				(53.5	)			(40.2	)		(4.9	)(o)		(45.1	)
Unrealized (loss) gain on derivative instruments, net		(1.3	)		1.3	(g)			—				(1.0	)		1.0	(g)		—
Gain on investments		—			—				—				0.3			—			0.3
Other, net		(15.9	)		—				(15.9	)			(7.1	)		4.8	(p)		(2.3	)
		(22.1	)		0.9				(21.2	)			(13.7	)		5.8			(7.9	)
Earnings from continuing operations before income taxes and minority interest		478.9			187.7				666.6				(190.1	)		739.4			549.3
Provision for income taxes		138.7			39.7	(h)			178.4				74.0			84.5	(q)		158.5
Minority interest		0.4			—				0.4				0.1			—			0.1
Earnings from continuing operations		339.8			148.0				487.8				(264.2	)		654.9			390.7
Discontinued operations:
Loss from discontinued operations, net of applicable income tax benefit of $0.4 million		(0.8	)		0.8	(i)			—				—			—			—
Gain on sale of discontinued operations, net of tax of $0.9 million		—			—				—				—			—			—
Discontinued operations		(0.8	)		0.8				—				—			—			—
Net earnings	$	339.0		$	148.8			$	487.8			$	(264.2	)	$	654.9		$	390.7
Basic earnings per share:
Continuing operations	$	1.11						$	1.60			$	(0.91	)				$	1.34
Discontinued operations		—							—				—						—
Net basic earnings per share	$	1.11						$	1.60			$	(0.91	)				$	1.34
Diluted earnings per share:
Continuing operations	$	1.10						$	1.58			$	(0.91	)				$	1.32
Discontinued operations		—							—				—						—
Net diluted earnings per share	$	1.10						$	1.58			$	(0.91	)				$	1.32
Weighted average number of common shares outstanding:
Basic		304.9							304.9				290.7						290.7
Diluted		308.3							308.3				290.7						296.3
Selected ratios as a percentage of product net sales
Selling, general and administrative		43.3	%						42.6	%			44.5	%					42.2	%
Research and development		18.8	%						16.3	%			42.4	%					16.0	%

(a) Corneal fair market value inventory roll-out adjustment of $0.5 million and integration and transition costs related to the acquisition of Corneal and Inamed of $0.2 million

-more-

9-9-9

(b)	Integration and transition costs related to the acquisitions of Corneal and Inamed of $6.8 million and $4.3 million, respectively, settlement of an unfavorable pre-existing Corneal distribution contract for $2.3 million, and $6.4 million legal settlement of a patent dispute assumed in the Inamed acquisition
(c)	In-process research and development charge related to the acquisition of EndoArt
(d)	Amortization of acquired intangible assets
(e)	Net restructuring charges
(f)	Interest income related to income tax settlements
(g)	Unrealized gain (loss) on the mark-to-market adjustment to derivative instruments
(h)	Total tax effect for non-GAAP pre-tax adjustments and other income tax adjustments, consisting of the following amounts (in millions):

Non-GAAP pre-tax adjustments of $187.7 million	$	(38.1	)
Favorable recovery of previously paid state income taxes		(1.6	)
	$	(39.7	)

(i)	Discontinued operations
(j)	Integration and transition costs related to the acquisition of Inamed, consisting of Cost of sales of $0.7 million; Selling, general and administrative expense of $14.6 million and Research and development expense of $0.2 million
(k)	Inamed fair-market value inventory adjustment roll-out of $47.9 million
(l)	Transition/duplicate operating expenses, consisting of Selling, general and administrative expense of $5.7 million and Research and development expense of $0.5 million
(m)	Contribution to Allergan Foundation of $28.5 million
(n)	In-process research and development charge of $579.3 million related to the acquisition of Inamed
(o)	Reversal of interest income on previously paid state income taxes and reversal of interest expense related to the resolution of uncertain tax positions
(p)	Accrued costs for a previously disclosed contingency involving non-income taxes in Brazil
(q)	Total tax effect for non-GAAP pre-tax adjustments and other income tax adjustments, consisting of the following amounts (in millions):

	Tax effect
Non-GAAP pre-tax adjustments of $739.4 million	$	(53.6	)
Resolution of uncertain tax positions and favorable recovery of previously paid state income taxes		(11.7	)
Change in valuation allowance		(17.2	)
Taxes related to intercompany transfers of trade businesses and net assets		0.8
Change in estimated income taxes on 2005 dividend repatriation		(2.8	)
	$	(84.5	)

-more-

10-10-10

ALLERGAN, INC.
Condensed Consolidated Balance Sheets
(Unaudited)

	September 28,			December 31,
In millions	2007			2006
Assets
Cash and equivalents	$	1,413.3		$	1,369.4
Trade receivables, net		478.3			386.9
Inventories		202.5			168.5
Other current assets		322.6			205.5
Total current assets		2,416.7			2,130.3
Property, plant and equipment, net		637.6			611.4
Intangible assets, net		1,105.9			1,043.6
Goodwill, net		1,961.8			1,833.6
Other noncurrent assets		175.5			148.2
Total assets	$	6,297.5		$	5,767.1
Liabilities and stockholders’ equity
Notes payable	$	39.6		$	102.0
Accounts payable		187.8			142.4
Accrued expenses and income taxes		416.1			413.7
Total current liabilities		643.5			658.1
Long-term debt		1,577.8			1,606.4
Other liabilities		470.1			359.5
Stockholders’ equity		3,606.1			3,143.1
Total liabilities and stockholders’ equity	$	6,297.5		$	5,767.1
DSO		45			43
DOH		107			108
Cash, net of debt	$	(204.1	)	$	(339.0	)
Debt-to-capital percentage		31.0	%		35.2	%

-more-

11-11-11

ALLERGAN, INC.
Reconciliation of Diluted Earnings Per Share
(Unaudited)

In millions, except per share amounts	Three months ended
	September 28,			September 29,
	2007			2006
Earnings from continuing operations	$	156.0		$	106.4
Non-GAAP pre-tax adjustments:
Net restructuring charges		11.0			8.6
Interest related to previously paid state income taxes and income tax settlements		—			(4.3	)
Amortization of acquired intangible assets		23.5			19.6
Corneal integration and transition costs		1.3			—
Inamed fair market-value inventory adjustment roll-out		—			23.9
Corneal fair market-value inventory adjustment roll-out		0.5			—
Inamed integration and transition costs		0.8			5.1
Contribution to Allergan Foundation		—			28.5
Unrealized (gain) loss on derivative instruments		(0.4	)		(0.2	)
Transition/duplicate operating expenses		—			0.3
		192.7			187.9
Tax effect for above items		(12.8	)		(27.8	)
Resolution of uncertain tax positions		—			3.9
Tax effect of dividend repatriation act		—			(2.8	)
Taxes related to intercompany transfers of trade businesses and net assets		—			0.8
Change in valuation allowance		—			(17.2	)
Adjusted diluted earnings from continuing operations	$	179.9		$	144.8
Weighted average number of shares issued		305.9			301.8
Net shares assumed issued using the treasury stock method for options and non-vested equity shares and share units outstanding during each period based on average market price		3.4			3.3
		309.3			305.1
Diluted earnings per share from continuing operations, as reported	$	0.50		$	0.35
Non-GAAP earnings per share adjustments:
Net restructuring charges		0.03			0.02
Interest related to previously paid state income taxes and income tax settlements		—			(0.01	)
Amortization of acquired intangible assets		0.05			0.04
Corneal integration and transition costs		—			—
Inamed fair market-value inventory adjustment roll-out		—			0.05
Corneal fair market-value inventory adjustment roll-out		—			—
Inamed integration and transition costs		—			0.01
Contribution to Allergan Foundation		—			0.06
Unrealized (gain) loss on derivative instruments		—			—
Resolution of uncertain tax positions		—			0.01
Tax effect of dividend repatriation		—			(0.01	)
Change in valuation allowance		—			(0.05	)
Adjusted diluted earnings per share from continuing operations	$	0.58		$	0.47
Year over year change			23.4%

-more-

12-12-12

ALLERGAN, INC.
Reconciliation of Diluted Earnings Per Share
(Unaudited)

In millions, except per share amounts	Nine months ended
	September 28,			September 29,
	2007			2006
Earnings (loss) from continuing operations	$	339.8		$	(264.2	)
Non-GAAP pre-tax adjustments:
Net restructuring charges		24.3			17.1
In-process research and development charge related to EndoArt		72.0			—
In-process research and development charge related to Inamed		—			579.3
Amortization of acquired intangible assets		70.0			39.1
Settlement of unfavorable Corneal distribution contract		2.3			—
Corneal integration and transition costs		6.9			—
Inamed fair market-value inventory adjustment roll-out		—			47.9
Corneal fair market-value inventory adjustment roll-out		0.5			—
Inamed integration and transition costs		4.4			15.5
Legal settlement of patent dispute		6.4			—
Contribution to Allergan Foundation		—			28.5
Accrued costs for a previously disclosed contingency involving non-income taxes in Brazil		—			4.8
Interest related to previously paid state income taxes and resolution of uncertain tax positions		(0.4	)		—
Unrealized (gain) loss on derivative instruments		1.3			1.0
Transition/duplicate operating expenses		—			6.2
		527.5			475.2
Tax effect for above items		(38.1	)		(53.6	)
Resolution of uncertain tax positions		—			(10.5	)
Tax effect of dividend repatriation act		—			(2.8	)
Taxes related to intercompany transfers of trade businesses and net assets		—			0.8
Change in valuation allowance		—			(17.2	)
State income tax recovery		(1.6	)		(1.2	)
Adjusted diluted earnings from continuing operations	$	487.8		$	390.7
Weighted average number of shares issued		304.9			290.7
Net shares assumed issued using the treasury stock method for options and non-vested equity shares and share units outstanding during each period based on average market price		3.4			3.4
Dilutive effect of assumed conversion of convertible notes outstanding		—			2.2
		308.3			296.3

-more-

13-13-13

In millions, except per share amounts	Nine months ended
	September 28,			September 29,
	2007			2006
Diluted earnings (loss) per share from continuing operations, as reported	$	1.10		$	(0.91	)
Effect of additional dilutive shares (a)		—			0.02
Non-GAAP earnings per share adjustments:
Net restructuring charges		0.06			0.05
In-process research and development charge related to EndoArt		0.23			—
In-process research and development charge related to Inamed		—			1.96
Amortization of acquired intangible assets		0.15			0.09
Settlement of unfavorable Corneal distribution contract		0.01			—
Corneal integration and transition costs		0.02			—
Inamed fair market-value inventory adjustment roll-out		—			0.11
Corneal fair market-value inventory adjustment roll-out		—			—
Inamed integration and transition costs		0.01			0.03
Legal settlement of patent dispute		0.01			—
Contribution to Allergan Foundation		—			0.06
Accrued costs for a previously disclosed contingency involving non-income taxes in Brazil		—			0.01
Interest related to previously paid state income taxes and resolution of uncertain tax positions		—			—
Unrealized (gain) loss on derivative instruments		—			—
Transition/duplicate operating expenses		—			0.01
Resolution of uncertain tax positions		—			(0.04	)
Tax effect of dividend repatriation		—			(0.01	)
Change in valuation allowance		—			(0.06	)
State income tax recovery		(0.01	)		—
Adjusted diluted earnings per share from continuing operations	$	1.58		$	1.32
Year over year change			19.7	%

(a) The number of shares used to calculate adjusted diluted earnings per share includes the dilutive effect of outstanding stock options and the assumed conversion of convertible notes.

-more-

14-14-14

ALLERGAN, INC.
Supplemental Non-GAAP Information
(Unaudited)

	Three months ended
	September 28,			September 29,			$ change in net sales								Percent change in net sales
	2007			2006			Total			Performance			Currency		Total			Performance			Currency
in millions
Eye Care Pharmaceuticals	$	457.7		$	403.4		$	54.3		$	42.9		$	11.4		13.5	%		10.6	%		2.9	%
Botox/Neuromodulator		296.7			237.7			59.0			52.4			6.6		24.8	%		22.0	%		2.8	%
Skin Care		29.5			34.3			(4.8	)		(4.8	)		—		(14.0	)%		(14.0	)%		0.0	%
Total Specialty Pharmaceuticals		783.9			675.4			108.5			90.5			18.0		16.1	%		13.4	%		2.7	%
Breast Aesthetics		69.7			54.1			15.6			13.5			2.1		28.8	%		25.0	%		3.8	%
Obesity Intervention		74.0			47.1			26.9			25.8			1.1		57.1	%		54.8	%		2.3	%
Facial Aesthetics		49.3			15.1			34.2			33.6			0.6		226.5	%		222.5	%		4.0	%
Core Medical Devices		193.0			116.3			76.7			72.9			3.8		66.0	%		62.7	%		3.3	%
Other		1.8			—			1.8			1.8			—	NA			NA			NA
Total Medical Devices		194.8			116.3			78.5			74.7			3.8		67.5	%		64.2	%		3.3	%
Product net sales	$	978.7		$	791.7		$	187.0		$	165.2		$	21.8		23.6	%		20.9	%		2.7	%
Alphagan P, Alphagan, and Combigan	$	89.8		$	80.0		$	9.8		$	7.4		$	2.4		12.2	%		9.3	%		2.9	%
Lumigan Franchise		100.4			86.4			14.0			11.2			2.8		16.2	%		13.0	%		3.2	%
Other Glaucoma		3.9			3.4			0.5			0.2			0.3		14.8	%		7.3	%		7.5	%
Restasis		88.2			69.3			18.9			18.9			—		27.3	%		27.3	%		0.0	%
Domestic		65.4	%		68.1	%
International		34.6	%		31.9	%

	Nine months ended
	September 28,			September 29,			$ change in net sales								Percent change in net sales
	2007			2006			Total			Performance			Currency		Total			Performance			Currency
in millions
Eye Care Pharmaceuticals	$	1,292.1		$	1,144.5		$	147.6		$	119.6		$	28.0		12.9	%		10.4	%		2.5	%
Botox/Neuromodulator		872.0			709.1			162.9			146.7			16.2		23.0	%		20.7	%		2.3	%
Skin Care		82.7			95.7			(13.0	)		(13.0	)		—		(13.6	)%		(13.6	)%		0.0	%
Total Specialty Pharmaceuticals		2,246.8			1,949.3			297.5			253.3			44.2		15.3	%		13.0	%		2.3	%
Breast Aesthetics		217.8			118.7			99.1			94.9			4.2		83.5	%		79.9	%		3.6	%
Obesity Intervention		195.9			92.9			103.0			101.0			2.0		110.9	%		108.7	%		2.2	%
Facial Aesthetics		141.6			33.0			108.6			107.4			1.2		329.1	%		325.5	%		3.6	%
Core Medical Devices		555.3			244.6			310.7			303.3			7.4		127.0	%		124.0	%		3.0	%
Other		1.8			—			1.8			1.8			—	NA			NA			NA
Total Medical Devices		557.1			244.6			312.5			305.1			7.4		127.8	%		124.7	%		3.1	%
Product net sales	$	2,803.9		$	2,193.9		$	610.0		$	558.4		$	51.6		27.8	%		25.5	%		2.3	%
Alphagan P, Alphagan, and Combigan	$	244.8		$	221.2		$	23.6		$	17.5		$	6.1		10.6	%		7.9	%		2.7	%
Lumigan Franchise		284.0			241.0			43.0			35.5			7.5		17.8	%		14.7	%		3.1	%
Other Glaucoma		11.4			12.0			(0.6	)		(1.3	)		0.7		(5.0	)%		(10.6	)%		5.6	%
Restasis		243.9			201.0			42.9			42.9			—		21.4	%		21.4	%		0.0	%
Domestic		65.7	%		67.6	%
International		34.3	%		32.4	%

-more-

15-15-15

ALLERGAN, INC.
Reconciliation of GAAP Diluted Earnings Per Share Guidance
To Adjusted Diluted Earnings Per Share Guidance
(Unaudited)

	Quarter 4, 2007
	Low		High
GAAP diluted earnings per share from continuing operations guidance (a)	$	0.51	$	0.52
Amortization of acquired intangible assets		0.05		0.05
Adjusted diluted earnings per share guidance	$	0.56	$	0.57

	Full Year 2007
	Low		High
GAAP diluted earnings per share from continuing operations guidance (a)	$	1.63	$	1.64
In-process research and development		0.23		0.23
Net restructuring charges		0.06		0.06
Settlement of unfavorable Corneal distribution contract		0.01		0.01
Corneal and Inamed integration and transition costs		0.02		0.02
Legal settlement of patent dispute		0.01		0.01
State income tax recovery		(0.01)		(0.01)
Amortization of acquired intangible assets		0.19		0.19
Adjusted diluted earnings per share guidance	$	2.14	$	2.15

(a)  GAAP diluted earnings per share guidance excludes any potential impact of future unrealized gains or losses on derivative instruments, restructuring charges and integration and transition costs that may occur but that are not currently known or determinable.

-more-

16-16-16

ALLERGAN, INC.
Recasted for Discontinued Operations
Condensed Consolidated Statements of Operations and
Reconciliation of Non-GAAP Adjustments
(Unaudited)

	Three months ended
in millions, except per share amounts	March 30, 2007
				Non-GAAP
	GAAP			Adjustments			Adjusted
Revenues
Product net sales	$	862.6		$	—		$	862.6
Other revenues		14.1			—			14.1
		876.7			—			876.7
Operating costs and expenses
Cost of sales (excludes amortization of acquired intangible assets)		151.8			—			151.8
Selling, general and administrative		386.4			(7.7	)(a)		378.7
Research and development		210.0			(72.0	)(b)		138.0
Amortization of acquired intangible assets		28.4			(23.0	)(c)		5.4
Restructuring charges		3.2			(3.2	)(d)		—
Operating income		96.9			105.9			202.8
Non-operating income (expense)
Interest income		15.4			(0.4	)(e)		15.0
Interest expense		(18.5	)		—			(18.5	)
Unrealized (loss) gain on derivative instruments, net		(1.3	)		1.3	(f)		—
Other, net		(1.1	)		—			(1.1	)
		(5.5	)		0.9			(4.6	)
Earnings from continuing operations before income taxes and minority interest		91.4			106.8			198.2
Provision for income taxes		46.7			10.4	(g)		57.1
Minority interest		(0.1	)		—			(0.1	)
Earnings from continuing operations		44.8			96.4			141.2
Loss from discontinued operations, net of applicable income tax of $0.5 million		(1.0	)		1.0			—
Net earnings	$	43.8		$	97.4		$	141.2
Basic earnings per share:
Continuing operations	$	0.15					$	0.47
Discontinued operations		(0.01	)					—
Net basic earnings per share	$	0.14					$	0.47
Diluted earnings per share:
Continuing operations	$	0.15					$	0.46
Discontinued operations		(0.01	)					—
Net diluted earnings per share	$	0.14					$	0.46
Weighted average number of common shares outstanding:
Basic		303.9						303.9
Diluted		307.3						307.3
Selected ratios as a percentage of product net sales
Selling, general and administrative		44.8	%					43.9	%
Research and development		24.3	%					16.0	%

(a)	Integration and transition costs related to the acquisition of Corneal and Inamed of $3.5 million and $1.9 million, respectively, and settlement of an unfavorable pre-existing Corneal distribution contract for $2.3 million
(b)	In-process research and development charge related to the acquisition of EndoArt
(c)	Amortization of acquired intangible assets
(d)	Net restructuring charges
(e)	Interest income related to income tax settlements
(f)	Unrealized gain (loss) on the mark-to-market adjustment to derivative instruments
(g)	Total tax effect for non-GAAP pre-tax adjustments and other income tax adjustments, consisting of the following amounts (in millions):

Non-GAAP pre-tax adjustments of $106.8 million	$	(10.9	)
Favorable recovery of previously paid state income taxes		0.5
	$	(10.4	)

-more-

17-17-17

ALLERGAN, INC.
Recasted for Discontinued Operations
Condensed Consolidated Statements of Operations and
Reconciliation of Non-GAAP Adjustments
(Unaudited)

	Three months ended
in millions, except per share amounts	June 29, 2007
				Non-GAAP
	GAAP			Adjustments			Adjusted
Revenues
Product net sales	$	962.6		$	—		$	962.6
Other revenues		15.3			—			15.3
		977.9			—			977.9
Operating costs and expenses
Cost of sales (excludes amortization of acquired intangible assets)		168.1			—			168.1
Selling, general and administrative		433.1			(10.2	)(a)		422.9
Research and development		154.0			—			154.0
Amortization of acquired intangible assets		29.0			(23.5	)(b)		5.5
Restructuring charges		10.1			(10.1	)(c)		—
Operating income		183.6			43.8			227.4
Non-operating income (expense)
Interest income		14.8			—			14.8
Interest expense		(17.5	)		—			(17.5	)
Unrealized (loss) gain on derivative instruments, net		(0.4	)		0.4	(d)		—
Other, net		(4.3	)		—			(4.3	)
		(7.4	)		0.4			(7.0	)
Earnings from continuing operations before income taxes and minority interest		176.2			44.2			220.4
Provision for income taxes		36.7			16.5	(e)		53.2
Minority interest		0.5			—			0.5
Earnings from continuing operations		139.0			27.7			166.7
Loss from discontinued operations, net of applicable income tax of $0.7 million		(1.2	)		1.2			—
Net earnings	$	137.8		$	28.9		$	166.7
Basic earnings per share:
Continuing operations	$	0.46					$	0.55
Discontinued operations		(0.01	)					—
Net basic earnings per share	$	0.45					$	0.55
Diluted earnings per share:
Continuing operations	$	0.45					$	0.54
Discontinued operations		—						—
Net diluted earnings per share	$	0.45					$	0.54
Weighted average number of common shares outstanding:
Basic		304.7						304.7
Diluted		308.2						308.2
Selected ratios as a percentage of product net sales
Selling, general and administrative		45.0	%					43.9	%
Research and development		16.0	%					16.0	%

(a)	Integration and transition costs related to the acquisition of Corneal and Inamed of $2.1 million and $1.7 million, respectively, and $6.4 million legal settlement of a patent dispute assumed in the Inamed acquisition
(b)	Amortization of acquired intangible assets
(c)	Net restructuring charges
(d)	Unrealized gain (loss) on the mark-to-market adjustment to derivative instruments
(e)	Total tax effect for non-GAAP pre-tax adjustments and other income tax adjustments, consisting of the following amounts (in millions):

Non-GAAP pre-tax adjustments of $44.2 million	$	(14.4	)
Favorable recovery of previously paid state income taxes		(2.1	)
	$	(16.5	)

-more-

18-18-18

ALLERGAN, INC.
Recasted for Discontinued Operations
Condensed Consolidated Statements of Operations and
Reconciliation of Non-GAAP Adjustments
(Unaudited)

	Six months Ended
in millions, except per share amounts	June 29, 2007
				Non-GAAP
	GAAP			Adjustments			Adjusted
Revenues
Product net sales	$	1,825.2		$	—		$	1,825.2
Other revenues		29.4			—			29.4
		1,854.6			—			1,854.6
Operating costs and expenses
Cost of sales (excludes amortization of acquired intangible assets)		319.9			—			319.9
Selling, general and administrative		819.5			(17.9	)(a)		801.6
Research and development		364.0			(72.0	)(b)		292.0
Amortization of acquired intangible assets		57.4			(46.5	)(c)		10.9
Restructuring charges		13.3			(13.3	)(d)		—
Operating income		280.5			149.7			430.2
Non-operating income (expense)
Interest income		30.2			(0.4	)(e)		29.8
Interest expense		(36.0	)		—			(36.0	)
Unrealized (loss) gain on derivative instruments, net		(1.7	)		1.7	(f)		—
Other, net		(5.4	)		—			(5.4	)
		(12.9	)		1.3			(11.6	)
Earnings from continuing operations before income taxes and minority interest		267.6			151.0			418.6
Provision for income taxes		83.4			26.9	(g)		110.3
Minority interest		0.4			—			0.4
Earnings from continuing operations		183.8			124.1			307.9
Loss from discontinued operations, net of applicable income tax benefit of $1.2 million		(2.2	)		2.2			—
Net earnings	$	181.6		$	126.3		$	307.9
Basic earnings per share:
Continuing operations	$	0.60					$	1.01
Discontinued operations		—						—
Net basic earnings per share	$	0.60					$	1.01
Diluted earnings per share:
Continuing operations	$	0.60					$	1.00
Discontinued operations		(0.01	)					—
Net diluted earnings per share	$	0.59					$	1.00
Weighted average number of common shares outstanding:
Basic		304.3						304.3
Diluted		307.8						307.8
Selected ratios as a percentage of product net sales
Selling, general and administrative		44.9	%					43.9	%
Research and development		19.9	%					16.0	%

(a)	Integration and transition costs related to the acquisition of Corneal and Inamed of $5.6 million and $3.6 million, respectively, settlement of an unfavorable pre-existing Corneal distribution contract for $2.3 million, and $6.4 million legal settlement of a patent dispute assumed in the Inamed acquisition
(b)	In-process research and development charge related to the acquisition of EndoArt
(c)	Amortization of acquired intangible assets
(d)	Net restructuring charges
(e)	Interest income related to income tax settlements
(f)	Unrealized gain (loss) on the mark-to-market adjustment to derivative instruments
(g)	Total tax effect for non-GAAP pre-tax adjustments and other income tax adjustments, consisting of the following amounts (in millions):

Non-GAAP pre-tax adjustments of $151.0 million	$	(25.3	)
Favorable recovery of previously paid state income taxes		(1.6	)
	$	(26.9	)

-more-

19-19-19

ALLERGAN, INC.
Recasted for Discontinued Operations
Reconciliation of Diluted Earnings Per Share
(Unaudited)

In millions, except per share amounts
	Three months
	ended March 30,
	2007
Earnings from continuing operations, as reported	$	44.8
Non-GAAP pre-tax adjustments:
Net restructuring charges		3.2
In-process research and development charge related to EndoArt		72.0
Amortization of acquired intangible assets		23.0
Settlement of unfavorable Corneal distribution contract		2.3
Corneal integration and transition costs		3.5
Inamed integration and transition costs		1.9
Interest related to previously paid state income taxes and income tax settlements		(0.4	)
Unrealized (gain) loss on derivative instruments		1.3
		151.6
Tax effect for above items		(10.9	)
Resolution of uncertain tax positions		—
State income tax recovery		0.5
Adjusted diluted earnings from continuing operations	$	141.2
Weighted average number of shares issued		303.9
Net shares assumed issued using the treasury stock method for options and non-vested equity shares and share units outstanding during each period based on average market price		3.4
		307.3
Diluted earnings per share from continuing operations, as reported	$	0.15
Non-GAAP earnings per share adjustments:
Net restructuring charges		0.01
In-process research and development charge related to EndoArt		0.23
Amortization of acquired intangible assets		0.05
Settlement of unfavorable Corneal distribution contract		0.01
Corneal integration and transition costs		0.01
Inamed integration and transition costs		—
Interest related to previously paid state income taxes and income tax settlements		—
Unrealized (gain) loss on derivative instruments		—
Adjusted diluted earnings per share from continuing operations	$	0.46

-more-

20-20-20

ALLERGAN, INC.
Recasted for Discontinued Operations
Reconciliation of Diluted Earnings Per Share
(Unaudited)

In millions, except per share amounts
	Three months
	ended June 29,
	2007
Earnings from continuing operations, as reported	$	139.0
Non-GAAP pre-tax adjustments:
Net restructuring charges		10.1
Amortization of acquired intangible assets		23.5
Corneal integration and transition costs		2.1
Inamed integration and transition costs		1.7
Legal settlement of patent dispute		6.4
Unrealized (gain) loss on derivative instruments		0.4
		183.2
Tax effect for above items		(14.4	)
State income tax recovery		(2.1	)
Adjusted diluted earnings from continuing operations	$	166.7
Weighted average number of shares issued		304.7
Net shares assumed issued using the treasury stock method for options and non-vested equity shares and share units outstanding during each period based on average market price		3.5
		308.2
Diluted earnings per share from continuing operations, as reported	$	0.45
Non-GAAP earnings per share adjustments:
Net restructuring charges		0.03
Amortization of acquired intangible assets		0.05
Corneal integration and transition costs		0.01
Inamed integration and transition costs		—
Legal settlement of patent dispute		0.01
Unrealized (gain) loss on derivative instruments		—
State income tax recovery		(0.01	)
Adjusted diluted earnings per share from continuing operations	$	0.54

-more-

21-21-21

ALLERGAN, INC.
Recasted for Discontinued Operations
Reconciliation of Diluted Earnings Per Share
(Unaudited)

In millions, except per share amounts

	Six months ended
	June 29,
	2007
Earnings from continuing operations, as reported	$	183.8
Non-GAAP pre-tax adjustments:
Net restructuring charges		13.3
In-process research and development charge related to EndoArt		72.0
Amortization of acquired intangible assets		46.5
Settlement of unfavorable Corneal distribution contract		2.3
Corneal integration and transition costs		5.6
Inamed integration and transition costs		3.6
Legal settlement of patent dispute		6.4
Interest related to previously paid state income taxes and resolution of uncertain tax positions		(0.4	)
Unrealized (gain) loss on derivative instruments		1.7
		334.8
Tax effect for above items		(25.3	)
State income tax recovery		(1.6	)
Adjusted diluted earnings from continuing operations	$	307.9
Weighted average number of shares issued		304.3
Net shares assumed issued using the treasury stock method for options and non-vested equity shares and share units outstanding during each period based on average market price		3.5
		307.8
Diluted earnings per share from continuing operations, as reported	$	0.60
Non-GAAP earnings per share adjustments:
Net restructuring charges		0.03
In-process research and development charge related to EndoArt		0.23
Amortization of acquired intangible assets		0.10
Settlement of unfavorable Corneal distribution contract		0.01
Corneal integration and transition costs		0.01
Inamed integration and transition costs		0.01
Legal settlement of patent dispute		0.01
Interest related to previously paid state income taxes and resolution of uncertain tax positions		—
Unrealized (gain) loss on derivative instruments		—
Adjusted diluted earnings per share from continuing operations	$	1.00

-more-

22-22-22

ALLERGAN, INC.
Recasted for Discontinued Operations
Supplemental Non-GAAP Information
(Unaudited)

	Three months ended
	March 30,			March 31,			$ change in net sales								Percent change in net sales
	2007			2006			Total			Performance			Currency		Total			Performance			Currency
in millions
Eye Care Pharmaceuticals	$	403.0		$	361.9		$	41.1		$	33.9		$	7.2		11.4	%		9.4	%		2.0	%
Botox/Neuromodulator		267.9			223.0			44.9			41.1			3.8		20.1	%		18.4	%		1.7	%
Skin Care		26.5			30.3			(3.8	)		(3.8	)		—		(12.5	)%		(12.5	)%		0.0	%
Total Specialty Pharmaceuticals		697.4			615.2			82.2			71.2			11.0		13.4	%		11.6	%		1.8	%
Breast Aesthetics		69.2			—			69.2			69.2			—	NA			NA			NA
Obesity Intervention		53.0			—			53.0			53.0			—	NA			NA			NA
Facial Aesthetics		43.0			—			43.0			43.0			—	NA			NA			NA
Core Medical Devices		165.2			—			165.2			165.2			—	NA			NA			NA
Product net sales	$	862.6		$	615.2		$	247.4		$	236.4		$	11.0		40.2	%		38.4	%		1.8	%
Alphagan P, Alphagan, and Combigan	$	77.5		$	71.0		$	6.5		$	4.7		$	1.8		9.2	%		6.7	%		2.5	%
Lumigan Franchise		89.0			72.9			16.1			13.9			2.2		22.1	%		19.1	%		3.0	%
Other Glaucoma		3.6			4.4			(0.8	)		(1.0	)		0.2		(19.4	)%		(23.5	)%		4.1	%
Restasis		78.4			66.1			12.3			12.3			—		18.7	%		18.7	%	NA
Domestic		66.4	%		67.4	%
International		33.6	%		32.6	%

-more-

23-23-23

ALLERGAN, INC.
Recasted for Discontinued Operations
Supplemental Non-GAAP Information
(Unaudited)

	Three months ended
	June 29,			June 30,			$ change in net sales								Percent change in net sales
	2007			2006			Total			Performance			Currency		Total			Performance			Currency
in millions
Eye Care Pharmaceuticals	$	431.4		$	379.2		$	52.2		$	42.8		$	9.4		13.8	%		11.3	%		2.5	%
Botox/Neuromodulator		307.4			248.4			59.0			53.2			5.8		23.8	%		21.4	%		2.3	%
Skin Care		26.7			31.1			(4.4	)		(4.4	)		—		(14.1	)%		(14.1	)%		0.0	%
Total Specialty Pharmaceuticals		765.5			658.7			106.8			91.6			15.2		16.2	%		13.9	%		2.3	%
Breast Aesthetics		78.9			64.6			14.3			12.2			2.1		22.1	%		18.9	%		3.3	%
Obesity Intervention		68.9			45.8			23.1			22.2			0.9		50.4	%		48.5	%		1.9	%
Facial Aesthetics		49.3			17.9			31.4			30.8			0.6		175.4	%		172.1	%		3.4	%
Core Medical Devices		197.1			128.3			68.8			65.2			3.6		53.6	%		50.8	%		2.8	%
Product net sales	$	962.6		$	787.0		$	175.6		$	156.8		$	18.8		22.3	%		19.9	%		2.4	%
Alphagan P, Alphagan, and Combigan	$	77.4		$	70.2		$	7.2		$	5.4		$	1.8		10.3	%		7.6	%		2.7	%
Lumigan Franchise		94.5			81.7			12.8			10.4			2.4		15.7	%		12.7	%		3.0	%
Other Glaucoma		3.9			4.2			(0.3	)		(0.5	)		0.2		(5.9	)%		(11.5	)%		5.6	%
Restasis		77.3			65.6			11.7			11.7			—		17.8	%		17.8	%		0.0	%
Domestic		65.3	%		67.2	%
International		34.7	%		32.8	%

	Six months ended
	June 29,			June 30,			$ change in net sales								Percent change in net sales
	2007			2006			Total			Performance			Currency		Total			Performance			Currency
in millions
Eye Care Pharmaceuticals	$	834.4		$	741.1		$	93.3		$	76.7		$	16.6		12.6	%		10.4	%		2.2	%
Botox/Neuromodulator		575.3			471.4			103.9			94.3			9.6		22.0	%		20.0	%		2.0	%
Skin Care		53.2			61.4			(8.2	)		(8.2	)		—		(13.4	)%		(13.4	)%		0.0	%
Total Specialty Pharmaceuticals		1,462.9			1,273.9			189.0			162.8			26.2		14.8	%		12.8	%		2.0	%
Breast Aesthetics		148.1			64.6			83.5			81.4			2.1		129.3	%		126.0	%		3.3	%
Obesity Intervention		121.9			45.8			76.1			75.2			0.9		166.2	%		164.3	%		1.9	%
Facial Aesthetics		92.3			17.9			74.4			73.8			0.6		415.6	%		412.2	%		3.4	%
Core Medical Devices		362.3			128.3			234.0			230.4			3.6		182.4	%		179.6	%		2.8	%
Product net sales	$	1,825.2		$	1,402.2		$	423.0		$	393.2		$	29.8		30.2	%		28.0	%		2.2	%
Alphagan P, Alphagan, and Combigan	$	155.0		$	141.2		$	13.8		$	10.1		$	3.7		9.8	%		7.2	%		2.6	%
Lumigan Franchise		183.5			154.5			29.0			24.3			4.7		18.7	%		15.7	%		3.0	%
Other Glaucoma		7.5			8.6			(1.1	)		(1.5	)		0.4		(12.8	)%		(17.7	)%		4.9	%
Restasis		155.7			131.7			24.0			24.0			—		18.2	%		18.2	%		0.0	%
Domestic		65.8	%		67.3	%
International		34.2	%		32.7	%

###